Renal Cell Carcinoma (RCC)
Conditions
Brief summary
The study aims to assess treatment patterns and outcomes in advanced RCC patients in real world clinical practices across various real world databases. Four databases will be evaluated
Interventions
TKIs
DRUGImmuno-oncology (IO)
IOs
Sponsors
Pfizer
Study design
Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age 20 years or older in the year of the index first line therapy prescription. * 2 or more RCC diagnoses (ICD-9: 189.0; ICD-10: C64.1, C64.2, C64.9) at least 30 days apart, in the 1 year prior to the index date until 30 days post index date. * 2 or more code for secondary malignancy codes indicating possible diagnoses for metastatic disease at least 30 days apart, in the 1 year prior to the index date until 30 days post index date. (ICD-9: xx-199.xx; ICD-10: C77-C79, except ICD9: 198.0 Secondary malignant neoplasm of the kidney and ICD10: C79.0 Secondary malignant neoplasm of the kidney and renal pelvis.) * Exploratory sensitivity analyses were performed to review patients with 1 or more diagnosis codes for advanced or metastatic RCC 12 months prior to the index date and 1 or more secondary malignancy codes around the RCC diagnosis dates. * Continuous enrollment from 12 months prior to the index date. Patients will be required to have continuous enrollment from their index date until the end of the available data. This will allow for sub-analysis of cohorts with 3 months, 6 months and 12 months of available data
Exclusion criteria
* Received advanced treatment prior to the study index date. * Prescription records with negative days of supply will be excluded from all the analyses except in cost variable calculation. The day of supply for claims with missing or 0 days will be imputed. * Only one RCC diagnosis in the 12 months prior or one mont post index date. * Patients with data for analysis (\< 3 months post index date)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With First Line Treatment Regimen | At index (anytime between 1-Apr-2018 and 31-Jul-2022 [approximately 52 months]); data collected and observed retrospectively over 35 months | Number of participants with first line treatment regimen prescribed following a primary and secondary diagnosis of advanced/metastatic disease is reported in this outcome measure. Index date was defined as the date of initiation of the aRCC treatment. |
| Number of Participants With Monotherapy and Combination Therapy | From the index date until end of enrollment, follow-up or death (maximum of 52 months); data collected and observed retrospectively over 35 months | Participants who received monotherapy and combination therapy by line of therapy is reported in this outcome measure. Index date was defined as the date of initiation of the aRCC treatment. |
| Time to First Line Therapy | From RCC diagnosis to index date (approximately 52 months); data collected and observed retrospectively over 35 months | Time to first line therapy was defined as length of time (days) from the first RCC diagnosis to first line therapy prescription. Index date was defined as the date of initiation of the aRCC treatment. |
| Duration of Treatment According to Each Line of Therapy | From the index date until end of enrollment, follow-up or death (maximum of 52 months); data collected and observed retrospectively over 35 months | Duration of treatment as per each line of therapy is reported in this outcome measure. Index date was defined as the date of initiation of the aRCC treatment. |
| Number of Participants With Treatment Continuation | From the index date until end of enrollment, follow-up or death (maximum of 52 months); data collected and observed retrospectively over 35 months | Treatment continuation was considered when there was no more than (\>) 30-day gap (i.e., persistent treatment) for the index medication during follow-up period. Index date was defined as the date of initiation of the aRCC treatment. |
| Number of Participants With Treatment Interruption | From the index date until end of enrollment, follow-up or death (maximum of 52 months); data collected and observed retrospectively over 35 months | Treatment Interruption was considered in participants with gaps in treatment greater than allowable gap but who restart the same medication with no indication of switching or augmentation. Index date was defined as the date of initiation of the aRCC treatment. |
| Time to Treatment Interruption | From the index date until end of enrollment, follow-up or death (maximum of 52 months); data collected and observed retrospectively over 35 months | Time from index medication to treatment discontinuation for those within treatment interruptions (\>30 day gaps). Represents the time between index and end of last treatment, including any treatment gaps. Index date was defined as the date of initiation of the aRCC treatment. |
| Number of Participants With Treatment Switch or Augmentation | From the index date until end of enrollment, follow-up or death (maximum of 52 months); data collected and observed retrospectively over 35 months | Number of participants who had treatment switch or augmentation were reported in this outcome measure. Augmentation was defined as addition of treatment to initial therapy prescribed, i.e, initiation of a new therapy different from the initial therapy while continuation of the initial therapy. Index date was defined as the date of initiation of the aRCC treatment. |
| Number of Participants According to Lines of Therapy | From the index date until end of enrollment, follow-up or death (maximum of 52 months); data collected and observed retrospectively over 35 months | Number of participants as per the lines of treatment were reported in this outcome measure. Index date was defined as the date of initiation of the aRCC treatment. |
| Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | From the index date until end of enrollment, follow-up or death (maximum of 52 months); data collected and observed retrospectively over 35 months | Number of participants according to the sequence of therapies received for mRCC were reported in this outcome measure. Index date was defined as the date of initiation of the aRCC treatment. |
| Number of Participants According to Their Status at End of Follow-up | At end of enrollment, follow-up or death (maximum of 52 months) (data collected and observed retrospectively over 35 months) | Number of participants according to their status (death, end of enrollment and end of data availability) at end of follow-up were observed and included in this outcome measure. Index date was defined as the date of initiation of the aRCC treatment. |
| Time to Treatment Failure (TTF) | From the index date until end of enrollment, follow-up or death (maximum of 52 months); data collected and observed retrospectively over 35 months | TTF was defined as the time from first-line therapy start to treatment discontinuation for any reason, including switched, augmented therapy, end of enrollment or death. Index date was defined as the date of initiation of the aRCC treatment. |
| Percentage of Participants With Treatment Discontinuation | From the index date until end of enrollment, follow-up or death (maximum of 52 months); data collected and observed retrospectively over 35 months | Percentage of participants with treatment discontinuation was defined as the percentage of participants with gap in therapy greater than 30 days and who did not begin a new treatment. Index date was defined as the date of initiation of the aRCC treatment. |
| Percentage of Participants Alive at 3 Months | At 3 months (data collected and observed retrospectively over 35 months) | Percentage of participants who were alive at 3 months is reported in this outcome measure. |
| Percentage of Participants Alive at 6 Months | At 3 months (data collected and observed retrospectively over 35 months) | Percentage of participants who were alive at 6 months is reported in this outcome measure. |
| Percentage of Participants Alive at 12 Months | At 3 months (data collected and observed retrospectively over 35 months) | Percentage of participants who were alive at 12 months is reported in this outcome measure. |
| Overall Survival | From the index date until end of enrollment, follow-up or death (maximum of 52 months); data collected and observed retrospectively over 35 months | OS is defined as the length of time from index date to participant's death. Index date was defined as the date of initiation of the aRCC treatment. |
Countries
United States
Participant flow
Recruitment details
Participants diagnosed with advanced/metastatic renal cell carcinoma (RCC) who initiated treatment for aRCC between 1-Apr-2018 and 31-Jul-2022 were observed. Data was collected retrospectively from various real world claims databases (Truven, Optum, Pharmetrics and the PanTher). Index date was the date of initiation of the aRCC treatment. Data was collected and observed for approximately 35 months (02 December 2019 to 28 October 2022) of this study.
Pre-assignment details
A total of 355 participants were included in the study.
Participants by arm
| Arm | Count |
|---|---|
| Axitinib + Pembrolizumab Participants diagnosed with aRCC who initiated treatment with axitinib + pembrolizumab between 1-Apr-2018 and 31-Jul-2022 were included and observed retrospectively in this study. | 340 |
| Axitinib + Avelumab Participants diagnosed with aRCC initiated treatment with axitinib + avelumab between 1-Apr-2018 and 31-Jul-2022 were included and observed retrospectively in this study. | 15 |
| Total | 355 |
Baseline characteristics
| Characteristic | Axitinib + Avelumab | Total | Axitinib + Pembrolizumab |
|---|---|---|---|
| Age, Continuous | 66.87 Years STANDARD_DEVIATION 10.45 | 64.25 Years STANDARD_DEVIATION 10.91 | 64.13 Years STANDARD_DEVIATION 10.93 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 1 Participants | 25 Participants | 24 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 8 Participants | 245 Participants | 237 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 6 Participants | 85 Participants | 79 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 3 Participants | 3 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants | 19 Participants | 19 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 4 Participants | 94 Participants | 90 Participants |
| Race (NIH/OMB) White | 11 Participants | 239 Participants | 228 Participants |
| Sex: Female, Male Female | 3 Participants | 108 Participants | 105 Participants |
| Sex: Female, Male Male | 12 Participants | 247 Participants | 235 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 161 / 340 | 11 / 15 |
| other Total, other adverse events | 0 / 0 | 0 / 0 |
| serious Total, serious adverse events | 0 / 0 | 0 / 0 |
Outcome results
Primary
Duration of Treatment According to Each Line of Therapy
Duration of treatment as per each line of therapy is reported in this outcome measure. Index date was defined as the date of initiation of the aRCC treatment.
Time frame: From the index date until end of enrollment, follow-up or death (maximum of 52 months); data collected and observed retrospectively over 35 months
Population: All eligible participants whose data were retrieved and observed in this study. Here, 'Number Analyzed' signifies number of participants evaluable for the specified rows.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Axitinib + Pembrolizumab | Duration of Treatment According to Each Line of Therapy | Second Line Therapy | 5.38 Days |
| Axitinib + Pembrolizumab | Duration of Treatment According to Each Line of Therapy | Sixth Line Therapy | 4.03 Days |
| Axitinib + Pembrolizumab | Duration of Treatment According to Each Line of Therapy | Third Line Therapy | 4.03 Days |
| Axitinib + Pembrolizumab | Duration of Treatment According to Each Line of Therapy | First Line Therapy | 11.97 Days |
| Axitinib + Pembrolizumab | Duration of Treatment According to Each Line of Therapy | Fourth Line Therapy | 2.75 Days |
| Axitinib + Pembrolizumab | Duration of Treatment According to Each Line of Therapy | Fifth Line Therapy | 2.53 Days |
| Axitinib + Avelumab | Duration of Treatment According to Each Line of Therapy | First Line Therapy | 5.90 Days |
| Axitinib + Avelumab | Duration of Treatment According to Each Line of Therapy | Fifth Line Therapy | 0.90 Days |
| Axitinib + Avelumab | Duration of Treatment According to Each Line of Therapy | Fourth Line Therapy | 3.57 Days |
| Axitinib + Avelumab | Duration of Treatment According to Each Line of Therapy | Second Line Therapy | 2.58 Days |
| Axitinib + Avelumab | Duration of Treatment According to Each Line of Therapy | Third Line Therapy | 3.43 Days |
Primary
Number of Participants According to Lines of Therapy
Number of participants as per the lines of treatment were reported in this outcome measure. Index date was defined as the date of initiation of the aRCC treatment.
Time frame: From the index date until end of enrollment, follow-up or death (maximum of 52 months); data collected and observed retrospectively over 35 months
Population: All eligible participants whose data were retrieved and observed in this study.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Axitinib + Pembrolizumab | Number of Participants According to Lines of Therapy | Fifth Line Therapy | 5 Participants |
| Axitinib + Pembrolizumab | Number of Participants According to Lines of Therapy | Third Line Therapy | 51 Participants |
| Axitinib + Pembrolizumab | Number of Participants According to Lines of Therapy | Sixth Line Therapy | 1 Participants |
| Axitinib + Pembrolizumab | Number of Participants According to Lines of Therapy | First Line Therapy | 340 Participants |
| Axitinib + Pembrolizumab | Number of Participants According to Lines of Therapy | Second Line Therapy | 148 Participants |
| Axitinib + Pembrolizumab | Number of Participants According to Lines of Therapy | Fourth Line Therapy | 14 Participants |
| Axitinib + Avelumab | Number of Participants According to Lines of Therapy | Second Line Therapy | 8 Participants |
| Axitinib + Avelumab | Number of Participants According to Lines of Therapy | First Line Therapy | 15 Participants |
| Axitinib + Avelumab | Number of Participants According to Lines of Therapy | Third Line Therapy | 3 Participants |
| Axitinib + Avelumab | Number of Participants According to Lines of Therapy | Fifth Line Therapy | 1 Participants |
| Axitinib + Avelumab | Number of Participants According to Lines of Therapy | Fourth Line Therapy | 1 Participants |
| Axitinib + Avelumab | Number of Participants According to Lines of Therapy | Sixth Line Therapy | 0 Participants |
Primary
Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC)
Number of participants according to the sequence of therapies received for mRCC were reported in this outcome measure. Index date was defined as the date of initiation of the aRCC treatment.
Time frame: From the index date until end of enrollment, follow-up or death (maximum of 52 months); data collected and observed retrospectively over 35 months
Population: All eligible participants whose data were retrieved and observed in this study.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Axitinib + Pembrolizumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | AXI, PEM/ Cabozantinib/ Pazopanib- Lenvatinib, Pembrolizumab/ Tivozanib | 1 Participants |
| Axitinib + Pembrolizumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | AXI, PEM/ Bevacizumab/ Cabozantinib | 1 Participants |
| Axitinib + Pembrolizumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | AXI, PEM/ Ipilimumab,Nivolumab/ Cabozantinib | 2 Participants |
| Axitinib + Pembrolizumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | AXI, PEM/ Bevacizumab- Awwb/ Bevacizumab/ Temsirolimus/ Bevacizumab- Awwb | 1 Participants |
| Axitinib + Pembrolizumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | AXI, PEM/ Ipilimumab,Nivolumab/ Cabozantinib,Ipilimumab,Nivolumab | 1 Participants |
| Axitinib + Pembrolizumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | AXI, PEM/ Bevacizumab-Awwb/ Cabozantinib | 1 Participants |
| Axitinib + Pembrolizumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | Avelumab, Axitinib/ Axitinib, Pembrolizumab | 0 Participants |
| Axitinib + Pembrolizumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | AXI, PEM/ Bevacizumab-Awwb, Everolimus | 1 Participants |
| Axitinib + Pembrolizumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | Axitinib,Pembrolizumab/ Ipilimumab,Nivolumab/ CSD | 1 Participants |
| Axitinib + Pembrolizumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | AXI, PEM/ Cabozantinib | 48 Participants |
| Axitinib + Pembrolizumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | AXI, PEM/ Ipilimumab,Nivolumab/ Everolimus,Lenvatinib | 1 Participants |
| Axitinib + Pembrolizumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | AXI, PEM/ Cabozantinib,Nivolumab | 6 Participants |
| Axitinib + Pembrolizumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | AXI, PEM/ Cabozantinib/ Cabozantinib, PEM/ Everolimus, Lenvatinib | 1 Participants |
| Axitinib + Pembrolizumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | AXI, PEM/ Lenvatinib | 2 Participants |
| Axitinib + Pembrolizumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | AXI, PEM/ Cabozantinib/ Clinical Study Drug (CSD)/ Everolimus, Lenvatinib/ Belzutifan | 1 Participants |
| Axitinib + Pembrolizumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | AXI, PEM/ Cabozantinib/Cabozantinib, Nivolumab | 4 Participants |
| Axitinib + Pembrolizumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | AXI, PEM/ Cabozantinib/ Everolimus,Lenvatinib/ Ipilimumab, Nivolumab | 1 Participants |
| Axitinib + Pembrolizumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | AXI, PEM/ Lenvatinib, Pembrolizumab | 1 Participants |
| Axitinib + Pembrolizumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | AXI, PEM/ Cabozantinib/ Everolimus, Lenvatinib, Tivozanib | 1 Participants |
| Axitinib + Pembrolizumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | AXI,PEM/ AXI,Leuprolide,PEM/ Abiraterone,AXI,PEM/Abiraterone,Axitinib,Leuprolide, PEM | 1 Participants |
| Axitinib + Pembrolizumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | AXI, PEM/ Cabozantinib/ Ipilimumab, Nivolumab | 2 Participants |
| Axitinib + Pembrolizumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | AXI, PEM/ Nivolumab/ Cabozantinib | 2 Participants |
| Axitinib + Pembrolizumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | AXI, PEM/ Cabozantinib/ Ipilimumab, Nivolumab/ Everolimus, Lenvatinib | 1 Participants |
| Axitinib + Pembrolizumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | AXI, PEM/Chlorambucil,Obinutuzumab/ Rituximab | 1 Participants |
| Axitinib + Pembrolizumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | AXI, PEM/ Cabozantinib/ Pazopanib/ Ipilimumab, Nivolumab | 1 Participants |
| Axitinib + Pembrolizumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | AXI, PEM/ Pazopanib | 2 Participants |
| Axitinib + Pembrolizumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | AXI, PEM/ Cabozantinib/Tivozanib/ Ipilimumab, Nivolumab | 1 Participants |
| Axitinib + Pembrolizumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | AXI, PEM/ Cabozantinib/ Everolimus, Lenvatinib | 4 Participants |
| Axitinib + Pembrolizumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | AXI, PEM/ Cabozantinib,CSD | 1 Participants |
| Axitinib + Pembrolizumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | AXI, PEM/ Cabozantinib,Nivolumab/ Everolimus,Lenvatinib | 1 Participants |
| Axitinib + Pembrolizumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | AXI, PEM/ Pazopanib/ Cabozantinib,Nivolumab | 1 Participants |
| Axitinib + Pembrolizumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | AXI, PEM/ Cabozantinib,Nivolumab,PEM/ Everolimus,Lenvatinib | 1 Participants |
| Axitinib + Pembrolizumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | AXI, PEM/ CSD | 2 Participants |
| Axitinib + Pembrolizumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | AXI, PEM/ Cabozantinib,PEM | 6 Participants |
| Axitinib + Pembrolizumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | AXI, PEM/ Sunitinib/Tivozanib/ Cabozantinib/ Tivozanib | 1 Participants |
| Axitinib + Pembrolizumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | AXI,PEM/ CSD,Cyclophosphamide,Daratumumab/Hyaluronidase- Fihj,Fludarabine/ Cabozantinib,Nivolumab | 1 Participants |
| Axitinib + Pembrolizumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | Avelumab, Axitinib/ Nivolumab | 0 Participants |
| Axitinib + Pembrolizumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | AXI, PEM/ CSD,Cyclophosphamide,Fludarabine/ Cabozantinib,Nivolumab | 1 Participants |
| Axitinib + Pembrolizumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | Avelumab,Axitinib | 0 Participants |
| Axitinib + Pembrolizumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | Axitinib,Pembrolizumab/CSD,Gemcitabine | 1 Participants |
| Axitinib + Pembrolizumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | Avelumab, Axitinib/ Cabozantinib | 0 Participants |
| Axitinib + Pembrolizumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | AXI, PEM/ Everolimus | 1 Participants |
| Axitinib + Pembrolizumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | AXI, PEM/ CSD/ Cabozantinib | 1 Participants |
| Axitinib + Pembrolizumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | AXI, PEM/ Everolimus/ Pazopanib | 1 Participants |
| Axitinib + Pembrolizumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | Avelumab,Axitinib/ Cabozantinib/ Cabozantinib, Nivolumab/ Tivozanib/ Pazopanib | 0 Participants |
| Axitinib + Pembrolizumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | AXI, PEM/ Everolimus,Lenvatinib | 5 Participants |
| Axitinib + Pembrolizumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | AXI, PEM/ Cabozantinib/ Everolimus, Lenvatinib/ Bevacizumab -Bvzr, Erlotinib | 1 Participants |
| Axitinib + Pembrolizumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | AXI, PEM/ Everolimus,Lenvatinib/ Cabozantinib/ Everolimus | 1 Participants |
| Axitinib + Pembrolizumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | AXI, PEM/ Everolimus,Lenvatinib,Pembrolizumab | 1 Participants |
| Axitinib + Pembrolizumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | Avelumab,Axitinib/ Cabozantinib/ Everolimus, Lenvatinib | 0 Participants |
| Axitinib + Pembrolizumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | AXI, PEM/ Gemcitabine,Paclitaxel Protein-Bound,Pembrolizumab | 1 Participants |
| Axitinib + Pembrolizumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | AXI, PEM-Doxorubicin,PEM/ Cabozantinib | 1 Participants |
| Axitinib + Pembrolizumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | AXI, PEM/ Hydroxyurea,Pembrolizumab | 1 Participants |
| Axitinib + Pembrolizumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | Avelumab,Axitinib/ Cabozantinib/ Pazopanib | 0 Participants |
| Axitinib + Pembrolizumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | AXI, PEM/ Ipilimumab,Nivolumab | 9 Participants |
| Axitinib + Pembrolizumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | AXI, PEM/ Cabozantinib/ Everolimus, Lenvatinib/ CSD | 1 Participants |
| Axitinib + Pembrolizumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | Avelumab, Axitinib/ Ipilimumab, Nivolumab | 0 Participants |
| Axitinib + Pembrolizumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | AXI, PEM/ Everolimus,Lenvatinib/ Cabozantinib,Nivolumab | 1 Participants |
| Axitinib + Pembrolizumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | AXI, PEM/ Leuprolide/ Bicalutamide,Leuprolide | 1 Participants |
| Axitinib + Pembrolizumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | AXI, PEM/ Nivolumab/ Cabozantinib,Nivolumab | 1 Participants |
| Axitinib + Pembrolizumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | Avelumab, Axitinib/ Pembrolizumab | 0 Participants |
| Axitinib + Pembrolizumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | AXI, PEM/ Pazopanib/ Cabozantinib/ Everolimus,Lenvatinib/ Sunitinib/ Tivozanib | 1 Participants |
| Axitinib + Pembrolizumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | AXI, PEM/ AXI, PEM/ Cabozantinib | 1 Participants |
| Axitinib + Pembrolizumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | AXI, PEM/ Pazopanib/ Everolimus,Lenvatinib | 1 Participants |
| Axitinib + Pembrolizumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | Axitinib,Pembrolizumab | 192 Participants |
| Axitinib + Pembrolizumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | AXI, PEM/ PEM | 7 Participants |
| Axitinib + Pembrolizumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | AXI, PEM/ Everolimus,Lenvatinib/ Ipilimumab,Nivolumab | 1 Participants |
| Axitinib + Pembrolizumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | AXI, PEM/ PEM,Sunitinib | 1 Participants |
| Axitinib + Pembrolizumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | Axitinib,Pembrolizumab/ Axitinib (PEM-AXI), leuprolide, Pembrolizumab | 1 Participants |
| Axitinib + Pembrolizumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | AXI, PEM/ Sunitinib/ Pembrolizumab,Sunitinib | 1 Participants |
| Axitinib + Pembrolizumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | AXI, PEM/ Cabozantinib/Bevacizumab- Awwb | 1 Participants |
| Axitinib + Avelumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | AXI, PEM/ Sunitinib/ Pembrolizumab,Sunitinib | 0 Participants |
| Axitinib + Avelumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | Avelumab, Axitinib/ Axitinib, Pembrolizumab | 1 Participants |
| Axitinib + Avelumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | Avelumab, Axitinib/ Nivolumab | 1 Participants |
| Axitinib + Avelumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | AXI,PEM/ AXI,Leuprolide,PEM/ Abiraterone,AXI,PEM/Abiraterone,Axitinib,Leuprolide, PEM | 0 Participants |
| Axitinib + Avelumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | AXI, PEM/ Cabozantinib/Bevacizumab- Awwb | 0 Participants |
| Axitinib + Avelumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | AXI, PEM/ Cabozantinib/ Clinical Study Drug (CSD)/ Everolimus, Lenvatinib/ Belzutifan | 0 Participants |
| Axitinib + Avelumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | AXI, PEM/ Cabozantinib/ Everolimus, Lenvatinib | 0 Participants |
| Axitinib + Avelumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | AXI, PEM/ Cabozantinib/ Everolimus, Lenvatinib/ CSD | 0 Participants |
| Axitinib + Avelumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | AXI, PEM/ Cabozantinib/ Pazopanib/ Ipilimumab, Nivolumab | 0 Participants |
| Axitinib + Avelumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | AXI, PEM/ Cabozantinib,CSD | 0 Participants |
| Axitinib + Avelumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | AXI, PEM/ Cabozantinib,Nivolumab | 0 Participants |
| Axitinib + Avelumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | AXI, PEM/ Cabozantinib,PEM | 0 Participants |
| Axitinib + Avelumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | AXI, PEM/Chlorambucil,Obinutuzumab/ Rituximab | 0 Participants |
| Axitinib + Avelumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | AXI, PEM/ CSD | 0 Participants |
| Axitinib + Avelumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | Axitinib,Pembrolizumab/CSD,Gemcitabine | 0 Participants |
| Axitinib + Avelumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | AXI, PEM/ Everolimus,Lenvatinib/ Cabozantinib/ Everolimus | 0 Participants |
| Axitinib + Avelumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | AXI, PEM/ Everolimus,Lenvatinib/ Cabozantinib,Nivolumab | 0 Participants |
| Axitinib + Avelumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | AXI, PEM/ Everolimus,Lenvatinib/ Ipilimumab,Nivolumab | 0 Participants |
| Axitinib + Avelumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | AXI, PEM/ Ipilimumab,Nivolumab | 0 Participants |
| Axitinib + Avelumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | AXI, PEM/ Ipilimumab,Nivolumab/ Cabozantinib,Ipilimumab,Nivolumab | 0 Participants |
| Axitinib + Avelumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | AXI, PEM/ Ipilimumab,Nivolumab/ Everolimus,Lenvatinib | 0 Participants |
| Axitinib + Avelumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | AXI, PEM/ Lenvatinib | 0 Participants |
| Axitinib + Avelumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | AXI, PEM/ Leuprolide/ Bicalutamide,Leuprolide | 0 Participants |
| Axitinib + Avelumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | AXI, PEM/ Nivolumab/ Cabozantinib | 0 Participants |
| Axitinib + Avelumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | AXI, PEM/ Pazopanib | 0 Participants |
| Axitinib + Avelumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | AXI, PEM/ Pazopanib/ Cabozantinib,Nivolumab | 0 Participants |
| Axitinib + Avelumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | AXI, PEM/ Sunitinib/Tivozanib/ Cabozantinib/ Tivozanib | 0 Participants |
| Axitinib + Avelumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | Avelumab, Axitinib/ Cabozantinib | 1 Participants |
| Axitinib + Avelumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | Avelumab,Axitinib/ Cabozantinib/ Cabozantinib, Nivolumab/ Tivozanib/ Pazopanib | 1 Participants |
| Axitinib + Avelumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | Avelumab,Axitinib/ Cabozantinib/ Everolimus, Lenvatinib | 1 Participants |
| Axitinib + Avelumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | Avelumab,Axitinib/ Cabozantinib/ Pazopanib | 1 Participants |
| Axitinib + Avelumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | Avelumab, Axitinib/ Ipilimumab, Nivolumab | 1 Participants |
| Axitinib + Avelumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | Avelumab, Axitinib/ Pembrolizumab | 1 Participants |
| Axitinib + Avelumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | Axitinib,Pembrolizumab | 0 Participants |
| Axitinib + Avelumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | Axitinib,Pembrolizumab/ Axitinib (PEM-AXI), leuprolide, Pembrolizumab | 0 Participants |
| Axitinib + Avelumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | AXI, PEM/ AXI, PEM/ Cabozantinib | 0 Participants |
| Axitinib + Avelumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | AXI, PEM/ Bevacizumab/ Cabozantinib | 0 Participants |
| Axitinib + Avelumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | AXI, PEM/ Bevacizumab- Awwb/ Bevacizumab/ Temsirolimus/ Bevacizumab- Awwb | 0 Participants |
| Axitinib + Avelumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | AXI, PEM/ Bevacizumab-Awwb/ Cabozantinib | 0 Participants |
| Axitinib + Avelumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | AXI, PEM/ Bevacizumab-Awwb, Everolimus | 0 Participants |
| Axitinib + Avelumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | AXI, PEM/ Cabozantinib | 0 Participants |
| Axitinib + Avelumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | AXI, PEM/ Cabozantinib/Cabozantinib, Nivolumab | 0 Participants |
| Axitinib + Avelumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | AXI, PEM/ Cabozantinib/ Cabozantinib, PEM/ Everolimus, Lenvatinib | 0 Participants |
| Axitinib + Avelumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | AXI, PEM/ Cabozantinib/ Everolimus, Lenvatinib/ Bevacizumab -Bvzr, Erlotinib | 0 Participants |
| Axitinib + Avelumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | AXI, PEM/ Cabozantinib/ Everolimus,Lenvatinib/ Ipilimumab, Nivolumab | 0 Participants |
| Axitinib + Avelumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | AXI, PEM/ Cabozantinib/ Everolimus, Lenvatinib, Tivozanib | 0 Participants |
| Axitinib + Avelumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | AXI, PEM/ Cabozantinib/ Ipilimumab, Nivolumab | 0 Participants |
| Axitinib + Avelumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | AXI, PEM/ Cabozantinib/ Ipilimumab, Nivolumab/ Everolimus, Lenvatinib | 0 Participants |
| Axitinib + Avelumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | AXI, PEM/ Cabozantinib/ Pazopanib- Lenvatinib, Pembrolizumab/ Tivozanib | 0 Participants |
| Axitinib + Avelumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | AXI, PEM/ Cabozantinib/Tivozanib/ Ipilimumab, Nivolumab | 0 Participants |
| Axitinib + Avelumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | AXI, PEM/ Cabozantinib,Nivolumab/ Everolimus,Lenvatinib | 0 Participants |
| Axitinib + Avelumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | AXI, PEM/ Cabozantinib,Nivolumab,PEM/ Everolimus,Lenvatinib | 0 Participants |
| Axitinib + Avelumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | AXI, PEM/ CSD/ Cabozantinib | 0 Participants |
| Axitinib + Avelumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | AXI,PEM/ CSD,Cyclophosphamide,Daratumumab/Hyaluronidase- Fihj,Fludarabine/ Cabozantinib,Nivolumab | 0 Participants |
| Axitinib + Avelumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | AXI, PEM/ CSD,Cyclophosphamide,Fludarabine/ Cabozantinib,Nivolumab | 0 Participants |
| Axitinib + Avelumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | AXI, PEM-Doxorubicin,PEM/ Cabozantinib | 0 Participants |
| Axitinib + Avelumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | AXI, PEM/ Everolimus | 0 Participants |
| Axitinib + Avelumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | AXI, PEM/ Everolimus/ Pazopanib | 0 Participants |
| Axitinib + Avelumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | AXI, PEM/ Everolimus,Lenvatinib | 0 Participants |
| Axitinib + Avelumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | AXI, PEM/ Everolimus,Lenvatinib,Pembrolizumab | 0 Participants |
| Axitinib + Avelumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | AXI, PEM/ Gemcitabine,Paclitaxel Protein-Bound,Pembrolizumab | 0 Participants |
| Axitinib + Avelumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | AXI, PEM/ Hydroxyurea,Pembrolizumab | 0 Participants |
| Axitinib + Avelumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | AXI, PEM/ Ipilimumab,Nivolumab/ Cabozantinib | 0 Participants |
| Axitinib + Avelumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | Axitinib,Pembrolizumab/ Ipilimumab,Nivolumab/ CSD | 0 Participants |
| Axitinib + Avelumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | AXI, PEM/ Lenvatinib, Pembrolizumab | 0 Participants |
| Axitinib + Avelumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | AXI, PEM/ Nivolumab/ Cabozantinib,Nivolumab | 0 Participants |
| Axitinib + Avelumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | AXI, PEM/ Pazopanib/ Cabozantinib/ Everolimus,Lenvatinib/ Sunitinib/ Tivozanib | 0 Participants |
| Axitinib + Avelumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | AXI, PEM/ Pazopanib/ Everolimus,Lenvatinib | 0 Participants |
| Axitinib + Avelumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | AXI, PEM/ PEM | 0 Participants |
| Axitinib + Avelumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | AXI, PEM/ PEM,Sunitinib | 0 Participants |
| Axitinib + Avelumab | Number of Participants According to Sequence of Therapies for Metastatic Renal Cell Carcinoma (mRCC) | Avelumab,Axitinib | 7 Participants |
Primary
Number of Participants According to Their Status at End of Follow-up
Number of participants according to their status (death, end of enrollment and end of data availability) at end of follow-up were observed and included in this outcome measure. Index date was defined as the date of initiation of the aRCC treatment.
Time frame: At end of enrollment, follow-up or death (maximum of 52 months) (data collected and observed retrospectively over 35 months)
Population: All eligible participants whose data were retrieved and observed in this study.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Axitinib + Pembrolizumab | Number of Participants According to Their Status at End of Follow-up | End of data availability | 75 Participants |
| Axitinib + Pembrolizumab | Number of Participants According to Their Status at End of Follow-up | Death | 161 Participants |
| Axitinib + Pembrolizumab | Number of Participants According to Their Status at End of Follow-up | End of enrollment | 104 Participants |
| Axitinib + Avelumab | Number of Participants According to Their Status at End of Follow-up | End of enrollment | 2 Participants |
| Axitinib + Avelumab | Number of Participants According to Their Status at End of Follow-up | End of data availability | 2 Participants |
| Axitinib + Avelumab | Number of Participants According to Their Status at End of Follow-up | Death | 11 Participants |
Primary
Number of Participants With First Line Treatment Regimen
Number of participants with first line treatment regimen prescribed following a primary and secondary diagnosis of advanced/metastatic disease is reported in this outcome measure. Index date was defined as the date of initiation of the aRCC treatment.
Time frame: At index (anytime between 1-Apr-2018 and 31-Jul-2022 [approximately 52 months]); data collected and observed retrospectively over 35 months
Population: All eligible participants whose data were retrieved and observed in this study.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Axitinib + Pembrolizumab | Number of Participants With First Line Treatment Regimen | 340 Participants |
| Axitinib + Avelumab | Number of Participants With First Line Treatment Regimen | 15 Participants |
Primary
Number of Participants With Monotherapy and Combination Therapy
Participants who received monotherapy and combination therapy by line of therapy is reported in this outcome measure. Index date was defined as the date of initiation of the aRCC treatment.
Time frame: From the index date until end of enrollment, follow-up or death (maximum of 52 months); data collected and observed retrospectively over 35 months
Population: All eligible participants whose data were retrieved and observed in this study. Here, 'Number Analyzed' signifies participants evaluable for specified rows.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Axitinib + Pembrolizumab | Number of Participants With Monotherapy and Combination Therapy | Combination therapy- Sixth Line | 0 Participants |
| Axitinib + Pembrolizumab | Number of Participants With Monotherapy and Combination Therapy | Combination therapy- Fifth Line | 0 Participants |
| Axitinib + Pembrolizumab | Number of Participants With Monotherapy and Combination Therapy | Monotherapy- First Line | 0 Participants |
| Axitinib + Pembrolizumab | Number of Participants With Monotherapy and Combination Therapy | Monotherapy- Second Line | 97 Participants |
| Axitinib + Pembrolizumab | Number of Participants With Monotherapy and Combination Therapy | Monotherapy- Third Line | 21 Participants |
| Axitinib + Pembrolizumab | Number of Participants With Monotherapy and Combination Therapy | Monotherapy- Fourth Line | 4 Participants |
| Axitinib + Pembrolizumab | Number of Participants With Monotherapy and Combination Therapy | Monotherapy- Fifth Line | 5 Participants |
| Axitinib + Pembrolizumab | Number of Participants With Monotherapy and Combination Therapy | Monotherapy- Sixth Line | 1 Participants |
| Axitinib + Pembrolizumab | Number of Participants With Monotherapy and Combination Therapy | Combination therapy- Third Line | 30 Participants |
| Axitinib + Pembrolizumab | Number of Participants With Monotherapy and Combination Therapy | Combination therapy- Fourth Line | 10 Participants |
| Axitinib + Pembrolizumab | Number of Participants With Monotherapy and Combination Therapy | Combination therapy- First Line | 340 Participants |
| Axitinib + Pembrolizumab | Number of Participants With Monotherapy and Combination Therapy | Combination therapy- Second Line | 51 Participants |
| Axitinib + Avelumab | Number of Participants With Monotherapy and Combination Therapy | Combination therapy- First Line | 15 Participants |
| Axitinib + Avelumab | Number of Participants With Monotherapy and Combination Therapy | Combination therapy- Second Line | 2 Participants |
| Axitinib + Avelumab | Number of Participants With Monotherapy and Combination Therapy | Monotherapy- Fourth Line | 1 Participants |
| Axitinib + Avelumab | Number of Participants With Monotherapy and Combination Therapy | Combination therapy- Fifth Line | 0 Participants |
| Axitinib + Avelumab | Number of Participants With Monotherapy and Combination Therapy | Combination therapy- Fourth Line | 0 Participants |
| Axitinib + Avelumab | Number of Participants With Monotherapy and Combination Therapy | Monotherapy- First Line | 0 Participants |
| Axitinib + Avelumab | Number of Participants With Monotherapy and Combination Therapy | Monotherapy- Fifth Line | 1 Participants |
| Axitinib + Avelumab | Number of Participants With Monotherapy and Combination Therapy | Monotherapy- Second Line | 6 Participants |
| Axitinib + Avelumab | Number of Participants With Monotherapy and Combination Therapy | Combination therapy- Third Line | 2 Participants |
| Axitinib + Avelumab | Number of Participants With Monotherapy and Combination Therapy | Monotherapy- Third Line | 1 Participants |
Primary
Number of Participants With Treatment Continuation
Treatment continuation was considered when there was no more than (\>) 30-day gap (i.e., persistent treatment) for the index medication during follow-up period. Index date was defined as the date of initiation of the aRCC treatment.
Time frame: From the index date until end of enrollment, follow-up or death (maximum of 52 months); data collected and observed retrospectively over 35 months
Population: All eligible participants whose data were retrieved and observed in this study.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Axitinib + Pembrolizumab | Number of Participants With Treatment Continuation | 21 Participants |
| Axitinib + Avelumab | Number of Participants With Treatment Continuation | 1 Participants |
Primary
Number of Participants With Treatment Interruption
Treatment Interruption was considered in participants with gaps in treatment greater than allowable gap but who restart the same medication with no indication of switching or augmentation. Index date was defined as the date of initiation of the aRCC treatment.
Time frame: From the index date until end of enrollment, follow-up or death (maximum of 52 months); data collected and observed retrospectively over 35 months
Population: All eligible participants whose data were retrieved and observed in this study.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Axitinib + Pembrolizumab | Number of Participants With Treatment Interruption | 171 Participants |
| Axitinib + Avelumab | Number of Participants With Treatment Interruption | 6 Participants |
Primary
Number of Participants With Treatment Switch or Augmentation
Number of participants who had treatment switch or augmentation were reported in this outcome measure. Augmentation was defined as addition of treatment to initial therapy prescribed, i.e, initiation of a new therapy different from the initial therapy while continuation of the initial therapy. Index date was defined as the date of initiation of the aRCC treatment.
Time frame: From the index date until end of enrollment, follow-up or death (maximum of 52 months); data collected and observed retrospectively over 35 months
Population: All eligible participants whose data were retrieved and observed in this study.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Axitinib + Pembrolizumab | Number of Participants With Treatment Switch or Augmentation | Treatment Switch | 146 Participants |
| Axitinib + Pembrolizumab | Number of Participants With Treatment Switch or Augmentation | Treatment Augmentation | 2 Participants |
| Axitinib + Avelumab | Number of Participants With Treatment Switch or Augmentation | Treatment Switch | 8 Participants |
| Axitinib + Avelumab | Number of Participants With Treatment Switch or Augmentation | Treatment Augmentation | 0 Participants |
Primary
Overall Survival
OS is defined as the length of time from index date to participant's death. Index date was defined as the date of initiation of the aRCC treatment.
Time frame: From the index date until end of enrollment, follow-up or death (maximum of 52 months); data collected and observed retrospectively over 35 months
Population: All eligible participants whose data were retrieved and observed in this study.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Axitinib + Pembrolizumab | Overall Survival | 29.43 Days |
| Axitinib + Avelumab | Overall Survival | 11.97 Days |
Primary
Percentage of Participants Alive at 12 Months
Percentage of participants who were alive at 12 months is reported in this outcome measure.
Time frame: At 3 months (data collected and observed retrospectively over 35 months)
Population: All eligible participants whose data were retrieved and observed in this study.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Axitinib + Pembrolizumab | Percentage of Participants Alive at 12 Months | 67.35 Percentage of participants |
| Axitinib + Avelumab | Percentage of Participants Alive at 12 Months | 40.00 Percentage of participants |
Primary
Percentage of Participants Alive at 3 Months
Percentage of participants who were alive at 3 months is reported in this outcome measure.
Time frame: At 3 months (data collected and observed retrospectively over 35 months)
Population: All eligible participants whose data were retrieved and observed in this study.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Axitinib + Pembrolizumab | Percentage of Participants Alive at 3 Months | 90.29 Percentage of participants |
| Axitinib + Avelumab | Percentage of Participants Alive at 3 Months | 86.67 Percentage of participants |
Primary
Percentage of Participants Alive at 6 Months
Percentage of participants who were alive at 6 months is reported in this outcome measure.
Time frame: At 3 months (data collected and observed retrospectively over 35 months)
Population: All eligible participants whose data were retrieved and observed in this study.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Axitinib + Pembrolizumab | Percentage of Participants Alive at 6 Months | 82.35 Percentage of participants |
| Axitinib + Avelumab | Percentage of Participants Alive at 6 Months | 66.67 Percentage of participants |
Primary
Percentage of Participants With Treatment Discontinuation
Percentage of participants with treatment discontinuation was defined as the percentage of participants with gap in therapy greater than 30 days and who did not begin a new treatment. Index date was defined as the date of initiation of the aRCC treatment.
Time frame: From the index date until end of enrollment, follow-up or death (maximum of 52 months); data collected and observed retrospectively over 35 months
Population: All eligible participants whose data were retrieved and observed in this study.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Axitinib + Pembrolizumab | Percentage of Participants With Treatment Discontinuation | 80 Percentage of participants |
| Axitinib + Avelumab | Percentage of Participants With Treatment Discontinuation | 80 Percentage of participants |
Primary
Time to First Line Therapy
Time to first line therapy was defined as length of time (days) from the first RCC diagnosis to first line therapy prescription. Index date was defined as the date of initiation of the aRCC treatment.
Time frame: From RCC diagnosis to index date (approximately 52 months); data collected and observed retrospectively over 35 months
Population: All eligible participants whose data were retrieved and observed in this study.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Axitinib + Pembrolizumab | Time to First Line Therapy | 29.00 Days |
| Axitinib + Avelumab | Time to First Line Therapy | 25.00 Days |
Primary
Time to Treatment Failure (TTF)
TTF was defined as the time from first-line therapy start to treatment discontinuation for any reason, including switched, augmented therapy, end of enrollment or death. Index date was defined as the date of initiation of the aRCC treatment.
Time frame: From the index date until end of enrollment, follow-up or death (maximum of 52 months); data collected and observed retrospectively over 35 months
Population: All eligible participants whose data were retrieved and observed in this study.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Axitinib + Pembrolizumab | Time to Treatment Failure (TTF) | 2.57 Months |
| Axitinib + Avelumab | Time to Treatment Failure (TTF) | 1.83 Months |
Primary
Time to Treatment Interruption
Time from index medication to treatment discontinuation for those within treatment interruptions (\>30 day gaps). Represents the time between index and end of last treatment, including any treatment gaps. Index date was defined as the date of initiation of the aRCC treatment.
Time frame: From the index date until end of enrollment, follow-up or death (maximum of 52 months); data collected and observed retrospectively over 35 months
Population: All eligible participants whose data were retrieved and observed in this study. Here, 'Overall Number of Participants Analyzed' signified participants evaluable for this outcome measure.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Axitinib + Pembrolizumab | Time to Treatment Interruption | 2.10 Months |
| Axitinib + Avelumab | Time to Treatment Interruption | 1.05 Months |